Renalytix Plc (RENX.L)
| Previous close | 28.00 |
| Open | 30.75 |
| Bid | 27.00 x 0 |
| Ask | 28.00 x 0 |
| Day's range | 27.00 - 30.75 |
| 52-week range | 10.00 - 150.00 |
| Volume | |
| Avg. volume | 766,073 |
| Market cap | 41.311M |
| Beta (5Y monthly) | 1.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.36 |
| Earnings date | 15 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.40 |
- PR Newswire
Pentwater Capital Management LP - Form 8.3 - Renalytix PLC
Pentwater Capital Management LP - Form 8.3 - Renalytix PLC
Globe NewswireRenalytix Announces Financing with Expected Size of up to $4 Million
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseas
- Globe Newswire
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce riskLONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024. In the release of the n
